ArticleFrontiers in immunology2022

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.

Shahryar Khoshtinat Nikkhoi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.